Amgen today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial ...

A Phase 2 study of daxdilimab is ongoing in patients with dermatomyositis and antisynthetase inflammatory myositis ... TEZSPIRE is enrolling patients with eosinophilic esophagitis.

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

Treatment failure for Plasmodium falciparum malaria is increasing in nonendemic countries. A session organized by the British Infection Association at European Society of Clinical Microbiology and ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of ...

Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and presents some key findings from recent patient research conducted in Europe ...

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

Juvenile myositis (JM) affects those under the age of 18 years. JM is known for causing muscle inflammation and skin rashes. These symptoms are the result of ongoing inflammation and swelling of the ...

2 In recent years, novel targeted therapies have been introduced to reduce reliance on corticosteroids, including complement inhibitors such as avacopan and biologics targeting eosinophilic pathways ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.